Quantitative measurement of APC-Resistant factor V clotting activity (FV-Leiden) and potential graduation of the associated thrombo-embolic risk Quantitative FV-L measurement

Article Sidebar

PDF Download
Published Jan 28, 2021
DOI: https://doi.org/10.18103/mra.v9i1.2314

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

PEYRAFITTE MARIE, Ms
HYPHEN BioMed research laboratory, 95130 Neuville sur Oise (France)
VISSAC ANNE MARIE, Ms
1. HYPHEN BioMed research laboratory, 95130 Neuville sur Oise (France)
AMIRAL JEAN
Scientific Hemostasis, 95130 Franconville (France)

Abstract

Coagulation Factor V (FV) is a key factor for regulating blood coagulation cascade, and it acts at the crossroads of the intrinsic and extrinsic pathways. It shows a dual activity as the procoagulant cofactor for Factor Xa in the prothrombinase complex, but it also supports an anticoagulant activity in combination with TFPI and Protein S. Its rapid cleavage by Activated Protein C (APC) complexed with Free Protein S (FPS), in presence of phospholipids and calcium, inhibits its activity and limits the propagation of blood coagulation, keeping it to where it is beneficial. Rapid inactivation of active FV by APC-FPS is essential for preventing the risk of thrombosis development. In 1993, Dahlbäck and coworkers reported an inherited disorder characterized by activated protein C resistance (APC-R) and associated to an increased occurrence of thromboembolic events in affected families. In 1994 Bertina demonstrated that this diathesis resulted from a Factor V mutation (R506Q), rendering this factor resistant to inactivation by APC. This mutated Factor V was called Factor V Leiden (FV-L). APTT based assays and molecular biology methods for detecting the mutation were developed, but these methods are only qualitative and classify tested individuals as normals, heterozygous or homozygous for the coagulation defect. Our group developed a quantitative assay for FV-L, which is described in this report, along with its performances. This assay allows to quantitate specifically FV-L coagulant activity, and to graduate its amount in heterozygous or homozygous patients. FV-L is absent in normal individuals and present in homozygous or heterozygous patients, accounting respectively for 100 % or 50 % of blood FV. Its amount is compared with FV clotting activity or antigenic concentration. Measured FV-L activities overlap between heterozygous patients with high FV and homozygous ones with low FV levels. This assay allows to better discriminate for the FV-L associated thrombotic risk, which depends on the effective FV-L concentration rather than on patients’ genetic status. This expectation is supported by literature review, which shows that FV-L concentrations correlate with presence of platelet released microparticles in patients carrying that mutation.

Keywords: Factor V Leiden, Quantitative assay, Activated Protein C, APC Resistance, Thrombosis

Article Details

How to Cite
MARIE, PEYRAFITTE; MARIE, VISSAC ANNE; JEAN, AMIRAL. Quantitative measurement of APC-Resistant factor V clotting activity (FV-Leiden) and potential graduation of the associated thrombo-embolic risk. Medical Research Archives, [S.l.], v. 9, n. 1, jan. 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2314>. Date accessed: 13 nov. 2024. doi: https://doi.org/10.18103/mra.v9i1.2314.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 9 No 1 (2021): Vol. 9 Issue 1 January 2021
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost. 1997 Jul;78(1):427-33
2. Amiral J. Measurement of blood activation markers applied to the early diagnosis of cardiovascular alterations. Expert Rev Mol Diagn. 2020 Jan;20(1):85-98.
3. Coller BS, Owen J, Jesty J, Horowitz D, Reitman MJ, Spear J, Yeh T, Comp PC. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis. 1987 Sep-Oct;7(5):456-62.
4. Dahlbäck B. Advances in understanding mechanisms of thrombophilic disorders. Hamostaseologie. 2020 Feb;40(1):12-21.
5. Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem. 1983 Feb 10;258(3):1914-20.
6. Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007 Sep;98(3):530-42.
7. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood. 1989 Nov 15;74(7):2426-32.
8. Dahlbäck B, Guo LJ, Livaja-Koshiar R, Tran S. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors. Res Pract Thromb Haemost. 2017 Dec 20;2(1):114-124.
9. Amiral J, Vissac AM, Seghatchian J. Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay. Transfus Apher Sci. 2017 Dec;56(6):906-913.
10. Santamaria S, Reglińska-Matveyev N, Gierula M, Camire RM, Crawley JTB, Lane DA, Ahnström J. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem. 2017 Jun 2;292(22):9335-9344.
11. Dahlbäck B. Low FV beneficial in FVFVIII deficiency? Blood. 2019 Nov 14;134(20):1686-1688.
12. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64-7
13. Mann KG, Lawler CM, Vehar GA, Church WR. Coagulation Factor V contains copper ion. J Biol Chem. 1984 Nov 10;259(21):12949-51.
14. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004-8.
15. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994 Nov 26;344(8935):1453-7.
16. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood. 1995 Jun 15;85(12):3405-11.
17. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem. 1995 Feb 24;270(8):4053-7.
18. Barhoover MA1, Kalafatis M. Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C. Blood Coagul Fibrinolysis. 2011 Jun;22(4):317-24
19. Bravo MC, Orfeo T, Mann KG, Everse SJ. Modeling of human factor Va inactivation by activated protein C. BMC Syst Biol. 2012 May 20;6:45.
20. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995 Mar 15;85(6):1504-8.
21. Holm J1, Zöller B, Berntorp E, Erhardt L, Dahlbäck B, Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries, J Intern Med. 1996 Mar;239(3):221-6
22. Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, Crim MT, Bass EB. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009 Jun 17;301(23):2472-85.
23. Bergrem A, Dahm AE, Jacobsen AF, Mowinckel MC, Sandvik L, Sandset PM. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br J Haematol. 2011 Jul;154(2):241-7.
24. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem. 1997 Sep;43(9):1678-83.
25. Simioni P, Tormene D, Prandoni P, Zerbinati P, Gavasso S, Cefalo P, Girolami A. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood. 2002 Mar 15;99(6):1938-42.
26. Lincz LF, Scorgie FE, Enjeti A, Seldon M. Variable plasma levels of Factor V Leiden correlate with circulating platelet microparticles in carriers of Factor V Leiden. Thromb Res. 2012 Feb;129(2):192-6.
27. Appel IM, Grimminck B, Geerts J, Stigter R, Cnossen MH, Beishuizen A. Age dependency of coagulation parameters during childhood and puberty. J Thromb Haemost. 2012 Nov;10(11):2254-63
28. Kadauke S, Khor B, Van Cott EM. Activated protein C resistance testing for factor V Leiden. Am J Hematol. 2014 Dec;89(12):1147-50.
29. Moore GW, Van Cott EM, Cutler JA, Mitchell MJ, Adcock DM; subcommittee on plasma coagulation inhibitors. Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH. J Thromb Haemost. 2019 Sep;17(9):1555-1561.
30. Trossaërt M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA, Modified APC resistance assay for patients on oral anticoagulants. Lancet. 1994 Dec 17;344(8938):1709
31. Lazovic Biljana, Milic Rade, Detanac A. Dzenana, Detanac S. Dzemail, Mulic Mersudin, Zugic Vladimir. Pulmonary thromboembolism and role of Factor V Leiden in its development - Review of literature. Sanamed 2019; 14(1): 103–106.
32. Lunghi B, Scanavini D, Girelli D, Legnani C, Bernardi F. Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels? J Thromb Haemost. 2005 Feb;3(2):415-6.
33. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000 Mar 1;95(5):1517-32.
34. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011 Jan;13(1):1-16.
35. Izuhara M1, Shinozawa K, Kitaori T, Katano K, Ozaki Y, Fukutake K, Sugiura-Ogasawara M. Genotyping analysis of the factor V Nara mutation, Hong Kong mutation, and 16 single-nucleotide polymorphisms, including the R2 haplotype, and the involvement of factor V activity in patients with recurrent miscarriage, Blood Coagul Fibrinolysis. 2017 Jun;28(4):323-328
36. Williamson D1, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood. 1998 Feb 15;91(4):1140-4.
37. Jadaon MM. Epidemiology of activated protein C resistance and factor V Leiden mutation in the mediterranean region. Mediterr J Hematol Infect Dis. 2011;3(1):e2011037.
38. van Mens TE, Levi M, Middeldorp S. Evolution of Factor V Leiden. Thromb Haemost. 2013 Jul;110(1):23-30.
39. Clark JS, Adler G, Salkic NN, Ciechanowicz A. Allele frequency distribution of 1691G >A F5 (which confers Factor V Leiden) across Europe, including Slavic populations. J Appl Genet. 2013 Nov;54(4):441-446.
40. Schöni R, Quehenberger P, Wu JR, Wilmer M. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA. Thromb Res. 2007;119(1):17-26.
41. Favaloro EJ, McDonald D. Futility of testing for factor V Leiden. Blood Transfus. 2012 Jul;10(3):260-3.
42. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997 Jan 15;89(2):397-402.Nogami K1, Shinozawa K, Ogiwara K, Matsumoto T, Amano K, Fukutake K, Shima M. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood. 2014 Apr 10;123(15):2420-8.